PolyPeptide Group AG, a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all proposals by its board of directors at an extraordinary general meeting held on October 26, 2026. The approvals include the election of five new board members and the removal of transfer restrictions and voting limitations from the company's articles of association, marking a significant governance shift for the SIX-listed company.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang, and Joonkyung Seong as members of the Board for a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected as chair of the Board, while Cheol Woo Ryu and Seungho Ryu were elected as members of the Remuneration and Nomination Committee, also for terms ending at the next annual general meeting. According to the press release issued via NEWMEDIAWIRE, all elections are subject to and effective as of the settlement of the public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide.
In addition, shareholders resolved to remove the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen) from PolyPeptide's articles of association. This resolution is subject to the satisfaction or waiver of all offer conditions set forth in the offer prospectus of Samsung Peptide AG dated August 31, 2026, except for the offer condition in section B.7.1(e) of the prospectus. The removal of these restrictions is a key step toward completing the tender offer and could significantly alter the company's shareholder structure and liquidity profile.
The board overhaul and the elimination of transfer restrictions are directly tied to Samsung Biologics' acquisition bid. Once the tender offer settles, the new board will take office, and the articles of association will be amended to eliminate barriers that previously limited share transfers and voting rights. For investors, this means greater flexibility in trading PolyPeptide shares and a board composition aligned with the acquirer's strategic direction. For the broader peptide CDMO industry, the move signals consolidation, as Samsung Biologics expands its footprint in the growing market for peptide-based active pharmaceutical ingredients, including GLP-1 therapies for metabolic diseases.
PolyPeptide, which dates back to 1952, operates a global network of six GMP-certified facilities across Europe, the U.S., and India, serving pharma and biotech customers from pre-pre-clinical to commercial stages. The company's shares trade on the SIX Swiss Exchange under the ticker PPGN. More information is available at polypeptide.com, and the company can be followed on LinkedIn. The full EGM results are available in the document PolyPeptide_EGM Results 2026_ENG.
